Peptide Comparison & Selection Guide

Selecting the appropriate peptide for research requires understanding key differences in receptor pathways, pharmacokinetic profiles, and target outcomes. Below is a detailed comparative breakdown of popular GLP-1 metabolic variants and Growth Hormone Secretagogues (GHS).

1. Metabolic & Incretin Peptides (GLP-1 & Multi-Agonists)

Incretin mimetic peptides target metabolic regulation, appetite signaling, and glucose homeostasis. Choosing between them depends on whether single-, dual-, or triple-receptor engagement is desired.

Feature / Compound	Semaglutide	Tirzepatide	Retatrutide
Receptor Class	Single Receptor Agonist	Dual Receptor Agonist	Triple Receptor Agonist
Target Receptors	GLP-1	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Mechanism of Action	Mimics GLP-1 to enhance insulin secretion, slow gastric emptying, and suppress appetite.	Combines GLP-1 appetite control with GIP receptor activation to further enhance metabolic rate and fat utilization.	Combines GLP-1 and GIP with Glucagon receptor stimulation, actively boosting basal energy expenditure alongside appetite suppression.
Pharmacokinetic Half-Life	~7 days	~5 days	~6 days
Primary Research Focus	Baseline metabolic control, appetite modulation, glucose tolerance.	Advanced weight management, enhanced insulin sensitivity.	Maximum weight management, metabolic rate elevation, fat oxidation.

Which Product Fits Your Research Focus?

• Choose Semaglutide if: You are seeking a well-studied, benchmark single-target GLP-1 agonist with proven, steady metabolic modulation.
• Choose Tirzepatide if: You are evaluating synergistic metabolic effects (GLP-1 + GIP dual pathways) for stronger appetite suppression and glucose regulation.
• Choose Retatrutide if: Your studies focus on cutting-edge triple-receptor kinetics, particularly energy expenditure via the glucagon pathway.

2. Growth Hormone Peptides & Secretagogues

Growth hormone secretagogues stimulate the production or release of endogenous Growth Hormone (GH) and IGF-1. They fall primarily into GHRH Analogs (stimulating GH production) and Ghrelin Receptor Agonists / GHRPs (triggering GH release).

Feature / Compound	Sermorelin	CJC-1295 (No DAC) / Mod GRF 1-29	CJC-1295 (with DAC)	Ipamorelin	MK-677 (Ibutamoren)
Peptide Class	GHRH Analog	GHRH Analog	GHRH Analog	Ghrelin Receptor Agonist (GHRP)	Oral Ghrelin Receptor Agonist
Mechanism	Stimulates natural pituitary GH pulses.	Modifies GHRH to resist rapid enzyme breakdown, producing sharp GH pulses.	Binds albumin via DAC to sustain elevated GH/IGF-1 levels for days.	Selectively binds ghrelin receptors to trigger pituitary GH release without spiking cortisol/prolactin.	Orally active secretagogue mimicking ghrelin to boost long-term GH & IGF-1.
Half-Life	~10–12 minutes	~30 minutes	~6–8 days	~2 hours	~24 hours
Administration	Injection (Pulsatile)	Injection (Pulsatile)	Injection (Sustained)	Injection (Pulsatile)	Oral (Daily)
Impact on Appetite / Cortisol	Minimal	Minimal	Minimal	None	Moderate increase in appetite

Synergy & Stacking (Combination Research)

• The CJC-1295 + Ipamorelin Stack: Combining a GHRH analog (like CJC-1295 No-DAC) with a GHRP (Ipamorelin) produces a synergistic effect—the GHRH instructs the pituitary to produce GH while the GHRP triggers its release simultaneously, delivering a significantly stronger physiological GH pulse than either compound alone.

Which Product Fits Your Research Focus?

• Choose Sermorelin or CJC-1295 (No DAC): If your research aims to replicate the body’s natural daily pulsatile GH secretion (e.g., night-time pulses).
• Choose CJC-1295 (with DAC): If continuous, long-acting elevation of IGF-1 levels is desired with infrequent administration.
• Choose Ipamorelin: If clean, highly selective GH release without affecting ghrelin, cortisol, or prolactin is required.
• Choose MK-677: If non-invasive (oral) administration and sustained 24-hour baseline elevation of GH/IGF-1 are required.